jeudi 19 octobre 2017

Onco Actu du 19 octobre 2017

1. Biologie

Many Pelvic Tumors in Women May Have Common Origin: Fallopian Tubes [NYU Langone Health]

3.1 Prévention - Tabac

Doctors to breathalyse smokers before allowing them NHS surgery [The Guardian]

4.10 Dép., diag. & prono. - FDA, EMA, NICE,...

Myriad's BRACAnalysis CDx® Supplementary PMA Accepted by FDA for Review as a Companion Diagnostic for Lynparza® (olaparib) in Metastatic Breast Cancer [Myriad]

5.10 Traitements - Essais

New targeted drug shows signs of effectiveness in first clinical trial [Institute of Cancer Research]

5.12.1 Immunothérapies - partenariats

Eli Lilly to Pursue mRNA Cancer Vaccines with CureVac Pact [Xconomy]

Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines [Lilly]

AbbVie and Harpoon Therapeutics Announce Immuno-Oncology Research Collaboration [AbbVie]

Eli Lilly is making a $1.8B leap into the mRNA field, targeting next-gen cancer vaccines [EndPoints]

5.12.2 Immunothérapies - CAR-T

FDA follows through with a groundbreaking OK for Yescarta, Gilead’s new CAR-T breakthrough [EndPoints]

Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy [Gilead]

Kite Nabs First Adult CAR-T Approval With Notable Uptick Of Cures [Xconomy]

FDA Approves Another Amazing And Costly Cancer-Killing Gene Therapy [Forbes]

FDA approves a game-changing treatment for blood cancer [STAT]

F.D.A. Approves Second Gene-Altering Treatment for Cancer [NY Times]

FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma [FDA]

Move over, Novartis: Kite and Gilead break into CAR-T market with early axi-cel nod [FiercePharma]

U.S. FDA approves Gilead cancer gene therapy; price set at $373,000 [Reuters]

5.12.5 Immunothérapies - Pharma

Bristol-Myers' Opdivo gets into high gear for new melanoma approval [FiercePharma]

5.13 WCLC

Merck’s KEYTRUDA® (pembrolizumab) More Than Doubled Median Overall Survival Compared to Chemotherapy After Two Years of Follow Up in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with High Levels of PD-L1 [Merck]

Padding its lung cancer lead, Merck's Keytruda helped PD-L1 patients live 30 months longer [FiercePharma]

5.2 Pharma

Ignyta NSCLC durability data set stage for Pfizer fight [FierceBiotech]

AstraZeneca's Lynparza ups the ante at the PARP table with FDA's speedy breast cancer review [FiercePharma]

5.2.1 Pharma - Partenariats

Researchers "drug the undruggable" through unique collaboration [Cancer Research UK]

5.4 Traitements - Economie

Drug Companies Make Eyedrops Too Big — And You Pay for the Waste [ProPublica]

Cancer drug prices rising far faster than inflation [The Guardian]

Drug Development Costs Revisited [In the Pipeline]

5.6 ESMO

First ESMO Award in Immuno-Oncology Goes to Laurence Zitvogel [ESMO]

6. Lutte contre les cancers

Norman Sharpless sworn in as director of the National Cancer Institute [NIH]

6.12 Ethique

Ethics and the Legalization of Physician-Assisted Suicide: An American College of Physicians Position Paper [Annals of Internal Medicine]